WebJan 11, 2024 · However, a clinical trial taking place soon at Johns Hopkins may have potential to bring this lofty goal to fruition, by using gene therapy to help repair the … WebApr 8, 2024 · About DT-DEC01. DT-DEC01 is a chimeric cell therapy. The advanced therapeutic medicinal product (ATMP) is made using Dystrogen's proprietary cell engineering technology which creates a DEC cell. Clinically, DEC cells have been shown to express CD56 at significantly higher levels than myoblasts from Duchenne patients.
Home - Dystrogen Therapeutics Corporation
WebSep 26, 2024 · Dystrogen Therapeutics, Corp. the leader in chimeric cell therapies, today announced positive 6-month results from an ongoing clinical study conducted in Poland under a hospital exemption protocol of DT-DEC01, the Company's investigational engineered cell therapy for Duchenne muscular dystrophy (DMD). ... -DEC01 is an … WebNov 5, 2024 · Dystrogen Therapeutics Corp has developed an engineered chimeric cell therapy which has been previously shown to restore muscle function in pre-clinical studies. For Duchenne's muscular... north little rock time
Our HD theraphy - Dystrogene Gene Therapie
WebSep 26, 2024 · MIAMI and WARSAW, Poland, Sept. 26, 2024 /PRNewswire/ -- Dystrogen Therapeutics, Corp. the leader in chimeric cell therapies, today announced positive 6-month results from an ongoing clinical ... WebSep 27, 2024 · Dystrogen Therapeutics’ DT-DEC01, an investigational chimeric cell therapy intended for the treatment of Duchenne muscular dystrophy (DMD), has demonstrated promising safety and efficacy in 6-month data from 3 patients treated in an on-going clinical trial in Poland. 1 WebDystrogen Gene Therapies is a life sciences company committed to developing therapies for rare genetic neurodegenerative disorders. Our most advance therapeutic candidate is for Huntington's disease (HD). how to say woo in spanish